Thursday, November 12, 2026

Elgato Stream Deck Plus Reaches Lowest Price Yet at $159.99 Across Major Retailers

Elgato's Stream Deck Plus is now at its lowest price ever for $159.99, making it an excellent choice for enhancing productivity and streamlining tasks.

LM Salvado

January 21, 2026

Elgato Stream Deck Plus Reaches Lowest Price Yet at $159.99 Across Major Retailers
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Elgato's Stream Deck Plus is currently available at its lowest price to date, according to The Verge AI. The device is on sale for $159.99 across major retailers including Amazon, Best Buy, and B&H Photo. This discounted price makes it an attractive option for users looking to enhance their productivity and streamline daily tasks.

The Stream Deck Plus offers a range of features designed to simplify workflow automation. It includes eight programmable buttons, four dials, and a small touchscreen. These components work together to allow users to customize their interactions with various applications and devices, from muting video calls to adjusting smart home settings.

According to The Verge AI, the Stream Deck Plus is an upgraded version of Elgato's standard Stream Deck. The Plus model introduces additional functionality with four rotary dials, which provide greater precision in controlling settings like volume or skipping tracks in a music playlist. This enhancement allows for more nuanced interactions compared to the standard model, which relies solely on buttons.

The Stream Deck Plus operates by allowing users to assign specific actions to each button and dial. For example, pressing a button can mute a microphone during a video call, while turning a dial can adjust the volume of a particular application. The touchscreen above the dials displays the current function of each control and enables users to navigate through different profiles or pages of programmed actions.

Elgato has also introduced software updates that enable users to assign up to three standard button or plug-in actions to each dial. This feature significantly increases the versatility of the Stream Deck Plus, making it a more robust tool for task automation.

The real-world impact of the Stream Deck Plus is evident in its ability to reduce the time and effort required to perform repetitive tasks. By automating common actions, users can focus more on their core activities, leading to increased productivity and efficiency. Additionally, the enhanced customization options provided by the dials make it particularly useful for media professionals who need precise control over audio and visual settings.

Looking ahead, potential future developments could include further software enhancements that expand the capabilities of the Stream Deck Plus. Users might also expect to see more integrations with popular applications and services, enhancing the device's utility even further. As technology evolves, the Stream Deck Plus may continue to adapt, offering even more streamlined solutions for task automation.

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com